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Objective: To review initial clinical presentation, treatment course, and results of ethanol embolotherapy for foot arte-
riovenous malformations (AVMs) and to analyze prognostic factors for treatment results.
Methods: Twenty-nine patients (mean age, 31.3 years; range, 9-59) who underwent ethanol embolotherapy between 1999
and 2012 were retrospectively reviewed. Initial clinical manifestation, medical history, treatment results of ethanol
embolotherapy, and major and minor complications were reviewed in detail. Two radiologists analyzed the extent of
AVM involvement, modiﬁed angiographic classiﬁcation by Cho et al, presence of feeding artery aneurysm, degree of
devascularization after embolotherapy, and treatment results. From the analysis, prognostic factors for ﬁnal outcome
were assessed.
Results: The most common symptom was pain (83%; 24/29), followed by ulcer (52%; 15/29), mass (48%; 14/29),
varicosity (38%; 11/29), and swelling (31%; 9/29). On baseline angiogram, lesion extent <25% of the foot occurred
in 62% (18/29) of cases. Between 25% and 33% comprised 24% (7/29), followed by more than 66% (10%; 3/29) and 33%
to 50% (3%; 1/29). The most common modiﬁed angiographic type was type IIIa (38%; 11/29), followed by IIIb (31%;
9/29), II (14%; 4/29), IIIa D IIIb (7%; 2/29), and II D IIIa (3%; 1/29). A total of 61 ethanol embolization sessions
(range, 1-10; median, 1) were performed in 29 patients. Seventeen of the 29 patients had only one intervention.
Transarterial approach was performed in six patients and direct puncture in 11 patients. Twelve patients required both
transarterial approach and direct puncture. One patient underwent both coil embolization via direct puncture and
transarterial ethanol embolotherapy. Cure (as judged by both completion angiography and clinical improvement) was
achieved in seven patients (24%; 7/29). Seventeen patients experienced improvement (59%; 17/29). In three patients, the
lesion showed no change (10%). Treatment failure was reported in two patients (7%; 2/29). Major complications
occurred in 24% (7/29) and minor complications in 52% (15/29). Skin necrosis (35%; 10/29) was the most common
minor complication. Lesion extent had a moderate correlation with outcome (P < .001; r [ 0.633). Lesions <25%
showed 100% success rates with >25% having 55%. There was no correlation between angiographic type and outcome
(P > .05; r [ 0.143).
Conclusions: Ethanol embolotherapy for foot AVMs can be as effective and safe as for other body parts. From the analysis
of angiographic ﬁndings, foot AVMs that involve <25% of the area of the foot are prone to show better treatment
outcomes from ethanol embolotherapy. (J Vasc Surg 2013;58:1619-26.)Arteriovenous malformations (AVMs) are deﬁned by
the shunting of high-velocity, low-resistance ﬂow from
the arterial vasculature into the venous system through
micro- or macroﬁstulous communications.1-3 Clinical
presentation, course, and treatment result are different
depending on the location, extent, and size of the ﬁstulous
connection.
Among the congenital vascular malformations, AVMs
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://dx.doi.org/10.1016/j.jvs.2013.06.074have been introduced, including surgical removal of the
AVM, feeding artery ligation, and interventional treat-
ments such as transarterial or transvenous embolization
and direct puncture. Interventional treatment has shown
better results with acceptable complication rates.4-9
Embolic agents, such as particulate materials, n-butyl
cyanoacrylate, ethanol, and coils, have been used.
Although ethanol has serious local and systemic adverse
effects compared with other embolic agents, ethanol
embolotherapy has better clinical and radiologic results
with an acceptable risk of morbidity.10-13
Many reports on the results of AVM treatments have
been published. Most of them have included a small
number of extremity AVM cases that involved only the
hand14 or hand and forearm.15 Although foot AVM can
have a signiﬁcant impact on the patient’s ambulatory func-
tion and life quality, there have been only a few reports on
foot AVM. These each involved a small number of foot
AVM cases, only as a part of the whole study sample, not
the whole study sample.4,9,11 Therefore, symptoms, treat-
ment options, results, and prognosis of foot AVMs are rela-
tively poorly known compared with AVMs involving other
parts of the body.1619
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the initial clinical presentation, transarterial or direct punc-
ture ethanol embolotherapy, and treatment results of foot
AVMs. We also analyzed predictive factors for treatment
results and prognosis on the basis of angiographic features
of foot AVM.
METHODS
Patients. A total of 33 patients with foot AVMs had
visited or were seen at the vascular malformation clinic at
our hospital from 1997 to 2012. Twenty-nine patients
(seven male and 22 female) were treated for embolization.
Treatment indications were the presence of subjective
clinical symptoms that made daily life uncomfortable (eg,
pain, pulsating mass), complicating signs of AVMs (eg,
ulcer, hemorrhage, secondary varicosities), and progressive
enlargement over time. Four patients were excluded
because of treatment refusal (n ¼ 2) or a lack of symptoms
(n ¼ 2). The mean age of the enrolled patients was
31.3 years (age range, 9-59 years). Written consent for
procedures was obtained from all patients after they had
been informed of the advantages and risks of the emboli-
zation procedure.
Medical record review. Electronic medical records
were available for all 29 patients and were reviewed in
detail. Emphasis was placed on initial clinical manifestation,
history (including surgery and interventional treatment),
and pulmonary artery pressure during the embolization
procedure. Major and minor complications were also
reviewed.
Clinical manifestation. Presenting symptoms and
signs included pulsating mass, pain, ulcer, swelling, vari-
cosity, and bone overgrowth. The most common symptom
was pain (83%; 24/29), followed by ulcer (52%; 15/29),
pulsating mass (48%; 14/29), varicosity (38%; 11/29),
and swelling (31%; 9/29). When the patients were classi-
ﬁed into two groups (group 1 [n ¼ 14], patients with
pulsating mass; group 2 [n ¼ 4], patients with ulcer),
group 1 showed 25 6 14.4 years (range, 9-52) and group
2, 37.6 6 13.1 years (range, 15-59) in terms of age
(P ¼ .0180). There was only one patient with bone over-
growth; his left lower extremity was slightly longer than
the right one. No patient had heart failure. Eight of
29 patients had undergone surgical treatment, including
excision, toe amputation, and ligation of superﬁcial veins
for varicosity at outside hospitals. Five of 29 patients had
a history of embolotherapy. Two of ﬁve patients underwent
skin graft surgery after embolotherapy because of skin
necrosis at outside hospitals. Radiation therapy and laser
ablation were also reported in two patients.
Embolization procedure. The embolization proce-
dure began with general anesthesia to control pain accord-
ing to previously reported protocols.10,16,17 In all patients,
pulmonary and systemic artery pressures were continuously
monitored after insertion of a Swan-Ganz catheter and
radial arterial catheterization, respectively, except in nine
patients. Two of the nine patients weighed less than 30 kg.
Seven patients were not monitored because they wereexpected to require less than one-third of the maximal
ethanol dose (1.0 mL/kg), which is considered to be safe.
A selective popliteal artery angiography was obtained
either from the ipsilateral or contralateral common femoral
artery approach, using a 4- or 5-F guiding catheter placed
through 4- or 5-F arterial sheaths, which were continuously
ﬂushed with heparinized saline. A nonionic iodine contrast
medium (Xenetix 300; Guerbet, Cedex, France) was used.
Through the analysis of the feeders, the draining veins and
hemodynamic status access route were determined. For
AVMs with less than three feeders or multiple feeders
and multiple draining, veins were transarterially ap-
proached ﬁrst. On the other hand, AVMs having tortuous
feeders or multiple feeders and one dominant draining
vein, were approached via direct puncture (Fig 1). For
transarterial embolotherapy, a 2- or 3-F microcatheter
(Progreat; Terumo Corporation, Tokyo, Japan, MicroFer-
ret; William Cook Europe ApS, Bjaeverskov, Denmark)
and microguidewire (Fathom; Boston Scientiﬁc, Natick,
Mass; Radiofous guidewire GT; Terumo Corporation,
Tokyo, Japan) were used to select feeders and to perform
selective angiography. We checked the hemodynamic char-
acteristics to determine the relationship between the
normal arteries of the foot and the nidus of the AVM in
terms of direct connection. After placing a microcatheter
as close as possible to nidus and conﬁrming its safety, we
test-injected contrast with a 1- or 3-mL syringe to optimize
the injection velocity of ethanol. A tourniquet was not used
during transarterial embolization. Ethanol was injected
manually under ﬂuoroscopic control, and the catheter
was ﬂushed with a small amount of contrast. The total
amount of ethanol was determined according to the
patient’s weight (less than 1.0 mL/kg), and the maximum
single bolus of ethanol did not exceed 0.1 mL/kg over
10 minutes. We waited about 8 to 10 minutes for ethanol
to contact the nidus and vessels. Once ethanol was admin-
istered, nitroglycerine (0.3-4.0 mg/kg/min) was continu-
ously administered simultaneously to control pulmonary
artery pressure. In case pulmonary artery pressure exceeded
25 mm Hg, a bolus of nitroglycerine (50-100 mg) was
injected. If pulmonary hypertension was refractory to nitro-
glycerin, we stopped the procedure and observed pulmo-
nary arterial pressure until it got back within normal
range. We alternated ethanol injection and 8- to 10-
minute waiting intervals until the target lesion of AVM
was completely embolized. For direct-puncture sclerother-
apy, the area of the percutaneous puncture was prepared
and draped. A 21- or 23-G scalp needle or 21-G micro-
puncture needle was used. Under ﬂuoroscopic guidance,
a draining vein was accessed as close as possible to the
nidus. We conﬁrmed the successful access by gentle aspira-
tion of blood. Then, angiography was performed with
a cuff inﬂated around or beyond the patient’s systolic arte-
rial pressure to ensure that the direct puncture was appro-
priate for sclerotherapy, delivering the alcohol as close to,
and toward the nidus. The amount of bolus ethanol injec-
tion was determined according to the patient’s body
weight and the blood velocity of the draining vein. When
Fig 1. Diagnostic and treatment planning algorithm. AVM,
Arteriovenous malformation.
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was not enough contact time between ethanol and the
nidus or blood vessel, we ﬁrst embolized the draining
vein with microcoils (Micronester coils; Cook, Blooming-
ton, Ind). Pulmonary artery pressure was controlled with
nitroglycerin in the same manner as for transarterial embo-
lotherapy. The total amount of ethanol for one session was
limited to 1 mL/kg of body weight. Absolute (99%)
ethanol was used in most of the cases. For superﬁcially
located AVMs, diluted (50%-80%) ethanol was used. After
the embolization procedure, completion angiography was
performed. Patients were sent to recovery room and moni-
tored by an anesthesiologist. When the patients had high
pulmonary artery pressure (above 25 mm Hg) or received
a large amount of ethanol (larger than 1.0 mL/kg), they
were sent to the intensive care unit. All patients were
closely followed for possible complications and discharged
within 24 hours.
Follow-up. Follow-up evaluation with physical exami-
nation, color Doppler imaging, and computed tomographic
scan were performed. Additional embolization was recom-
mended if the symptoms and signs remained and recurred,
or if AVMs persisted in follow-up imaging studies. All
patients except two underwent clinical follow-up after the
last embolization session. The follow-up period was deﬁned
as the period between the date of the last embolization
session and the date of the patient’s last visit. The median
clinical follow-up period for these 27 patients was
15.8 months (range, 0.6-70.2 months). Fourteen patients
did not have any follow-up imaging examination.
Imaging analysis. By consensus, two radiologists
(Y.D. and D.H., with 20 years and 1 year experience in
interventional radiology, respectively) analyzed the extent
of AVM involvement, the angiographic type according
to a published classiﬁcation system,17 the presence of
feeding artery aneurysm, the degree of devascularization
after embolization, and the ﬁnal results. According to
the modiﬁed angiographic classiﬁcation, type I, deﬁned asarteriovenous ﬁstula, refers to at most three separate arteries
shunted to a single draining vein. Type II (arteriolovenous
ﬁstulas) is multiple arterioles shunted into a single vein.
Type IIIa (nondilatated arteriolovenulous ﬁstulas) has
multiple shunts between the arterioles and venules, and type
IIIb means dilatated ﬁstula. The extent of AVM involve-
ment, angiographic type, and degree of devascularization
were determined based on the completion angiogram with
visual assessment. The extent of AVM involvement was
determined according to the ratio of the involved area of
AVM to the total area of the foot. These ratios were clas-
siﬁed as <25%, 25% to 33%, 33% to 50%, 50% to 66%, and
>66%. The angiographic type was classiﬁed into type I, type
II, type IIIa, type IIIb, and mixed type.17 When AVM had
a mixed type, the major type was placed ﬁrst and the minor
type followed, for example, type IIIa þ II. The degree of
devascularization was assessed by comparing the initial
angiogram to the ﬁnal angiogram and was categorized as
100%, 76% to 99%, 50% to 75%, or <50%. The ﬁnal result
was determined considering both the degree of devascula-
rization and clinical outcome: complete resolution or cure,
partial resolution, no change or aggravation. Complete
resolution or cure was deﬁned as 100% devascularization
with no residual clinical symptoms or signs. Partial resolu-
tion was deﬁned as 50% to 99% devascularization with
improvement of the clinical symptoms or signs. No change
was deﬁned as less than 50% devascularization and
improvement or no change of the clinical symptoms or
signs. Aggravation was deﬁned as an aggravation of the
clinical symptoms or signs regardless of the degree of AVM
devascularization. Treatment failure was deﬁned as any
procedure that resulted in amputation of the foot or
instances when we could not treat the lesion. From the
analysis of the angiographic ﬁndings, we identiﬁed possible
predictive factors for the ﬁnal result.
Statistics. Median age was compared between group 1
and group 2 with the Mann-Whitney test. Correlations of
outcome with lesion extent and angiographic type were
analyzed with Spearman correlation. Statistical analysis
was performed using SPSS (v 11.5 for Windows; SPSS,
Chicago, Ill).
RESULTS
Clinical manifestations, angiographic features, and
treatment results were summarized in the Table.
Clinical manifestation. Presenting symptoms and
signs markedly improved in 19 patients (66%; 19/29).
Six patients showed partial improvement of their symptoms
and signs (21%; 6/29). There were four patients whose
symptoms and signs were unchanged.
Angiographic ﬁndings and embolization. On baseline
angiogram, lesion extent <25% occurred in 62% (18/29) of
cases. Lesions involving 25% to 33% of the foot comprised
24% (7/29), followed by lesions more than 66% (10%;
3/29), and lesions of 33% to 50% (3%; 1/29). The most
common modiﬁed angiographic type was type IIIa (38%;
11/29), followed by IIIb (31%; 9/29), II (14%; 4/29),
IIIa þ IIIb (7%; 2/29), and II þ IIIa (3%; 1/29). Feeding
Table. Summary of clinical manifestations, angiographic features, and treatment results
Patient no.
sex/age,
year
Symptom
and sign
Extent of
involvement
(%)
Angiographic
type
No.
of
sessions Approach
Major
complications
Minor
complications
Follow-up
period,
months
Degree of
devascularization
(%) Outcome
1/F/52 U, P >66 IIIa þ IIIb 3 D No SN 1.5 <50 NC
2/F/13 M <25 II 2 D and TA No No Loss 50w75 PR
3/F/47 U, P <25 IIIa 1 D No TG 13 76w99 PR
4/F/28 U, P <25 IIIa 2 D No SB, SN 35.7 76w99 PR
5/M/51 M, P <25 IIIb 1 D No SN, TSL 6.8 100 Cure
6/F/12 M <25 IIIa 1 D and TA No SC 52.8 100 Cure
7/F/59 U, P >66 IIIb 1 TA PAH, AR,
Hypo, K
No 14.9 <50 NC
8/F/29 U, P, M 33w50 IIIa 10 D and TA
(coil)
SN
(nonhealing)
No 33.5 NC Failure
9/F/54 U, P 25w33 IIIa 1 D No No Loss <50 Failure
10/F/30 U, M, P 25w33 IIIb 1 TA No No 1.7 50w75 PR
11/M/42 U, P, V 25w33 IIIb 3 D No SB 0.9 76w99 PR
12/F/9 M, P <25 IIIb 2 D and TA No No 1.4 76w99 PR
13/M/22 S, V 25w33 II þ IIIa 2 D and TA No TSL 7.7 76w99 PR
14/F/52 M, P <25 IIIa 1 D No SN 9.7 50w75 Cure
15/F/12 M, P <25 II 1 D and TA
(coil)
Embolization No 70.2 100 Cure
16/F/28 U, S, V, P <25 IIIa 1 D SN No 25.4 50w75 PR
17/M/42 U, S, V, P 25w33 IIIb 5 D and TA No SB, SN 13.5 76w99 PR
18/F/28 U, S, V, P >66 IIIa þ IIIb 1 D No VT, SN 22.7 <50 NC
19/F/38 S, V 25w33 IIIb 1 TA EKG; ST
change
SN, SB, SC 27.3 76w99 PR
20/F/25 M, P, S, V <25 IIIb 2 D and TA No SB, VT 1.9 76w99 PR
21/F/24 M, P, V <25 II 2 TA No TNP 7.2 76w99 PR
22/M/10 S, P, V, B <25 IIIa 9 TA and D No SN, SB 32.1 76w99 PR
23/F/26 M, P, V <25 II 1 D No No 6.3 100 Cure
24/F/35 U, S, V, P <25 IIIa 2 D No No 1.4 50w75 PR
25/M/12 M <25 II 1 TA and D No No 8.4 100 Cure
26/F/47 U, P, S <25 IIIa 1 TA and D No SN 4.5 50w75 PR
27/F/25 U, P 25w33 IIIb 1 TA and D No SB 0.6 50w75 PR
28/F/40 M, P <25 IIIb 1 TA No No 3 100 Cure
29/M/15 U, M, P <25 IIIa 1 TA No SB, SN 23.5 76w99 PR
AR, Arrhythmia; D, direct puncture; EKG, electrocardiogram; Hypo, hypotension; K, hypokalemia; M, pulsating mass; NC, No change; P, pain; PHA,
pulmonary artery hypertension; PR, partial resolution; SB, skin bullae; SC, skin color change; SN, skin necrosis; TA, transarterial approach; TG, toe gangrene;
TNP, transient nerve palsy; TSL, transient sensory loss; U, ulcer; V, varicosity; VT, venous thrombosis.
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acteristic ﬁnding of foot AVMs compared with that of hand
AVMs was that no foot AVM involved toes distal to the
metatarsophalangeal joints.
A total of 61 ethanol embolizations (range, 1-10;
median, 1) were performed in 29 patients over the past
15 years. Seventeen patients underwent only one emboliza-
tion session, 10 patients underwent two to ﬁve sessions,
and two patients underwent more than ﬁve sessions. The
route of approach was direct puncture and transarterial
combined (41%; 12/29), direct puncture only (38%; 11/
29), and transarterial only (21%; 6/29). Coils were used
via direct puncture in one patient. No patient underwent
coil embolization by transarterial approach.
Treatment results and statistical analysis. Cure was
achieved in seven patients (24%; 7/29). Seventeen patients
experienced partial resolution (59%; 17/29). In three
patients, the lesion showed no change (10%). Treatment
failure was reported in two patients (7%; 2/29).
For the correlation analysis between lesion extent and
outcome, the extent of the lesion was reclassiﬁed into
two groups (<25% and >25%). Lesions <25% showed100% success rates with >25% having 55%. The lesion
extent had a moderate correlation with outcome (P <
.001; r ¼ 0.633) (Figs 2 and 3). In the correlation analysis
between angiographic type and outcome, angiographic
type was regrouped into three types (types II, IIIa, and
IIIb). There was no correlation between angiographic
type and outcome (P > .05; r ¼ 0.143).
Minor and major complications. Minor complica-
tions occurred in 52% (15/29). These included skin bullae,
skin necrosis, skin color change, transient sensory loss, tran-
sient nerve palsy, and superﬁcial or deep vein thrombosis.
Skin necrosis (35%; 10/29 patients) was the most common
minor complication. With conservative treatment such as
daily dressing and oral antibiotics, skin necrosis improved
within 6 months. Skin bullae (28%; 8/29 patients), skin
color change (2/29 patients), transient sensory loss (2/
29 patients), and transient nerve palsy (1/29 patients)
required only conservative treatment to improve. Superﬁ-
cial/deep vein thrombosis (2/29 patients) involved the
peroneal vein, and the great saphenous vein and disap-
peared spontaneously during the follow-up period with
no sequelae.
Fig 2. Partial resolution via both direct-puncture sclerotherapy and intra-arterial embolotherapy. A 13-year-old boy
presented with swelling and varicosity in his left foot. A, A late arterial phase image of the angiogram shows a mixed
type (II þ IIIa) of arteriovenous malformation (AVM) that involves 25% to 33% of his left foot area and the calcaneus.
B and C, Two sessions of embolotherapy with a total of 37.9 mL of pure ethanol were performed via direct puncture of
bone AVM and intra-arterial approach. D, A late arterial phase image of the angiogram after treatment demonstrates
that approximately 90% of the AVM has been controlled, which means partial resolution. Inﬁltrative AVM remains.
Transient sensory loss of the treated foot has fully recovered.
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treatment was required in two patients with skin necrosis.
One of them underwent below-knee amputation because
of intractable pain, not skin necrosis itself. Another patientunderwent escarectomy and split-thickness skin graft, and
the skin necrosis ﬁnally abated. One patient with toe
gangrene fully recovered with the conservative treatment
of daily dressing. In one female patient, at the age of 59,
Fig 3. Arteriovenous malformation (AVM) resistant to ethanol sclerotherapy. A 28-year-old woman presented with
ulcer, pain, and swelling in her right foot. A, Type IIIa þ IIIb AVM involving >66% of her right foot on a late arterial
phase image of her right-foot angiogram. B, Sclerotherapy was performed via direct puncture with a total of 23 mL of
pure ethanol. C, A considerable extent (<50% devascularization) of AVM remains on completion angiogram. Follow-
up computed tomographic (CT) angiography showed AVM partially improved. However, symptoms and signs
remained. No further treatment was recommended.
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lemia developed after transarterial injection of 25 mL of
ethanol. Embolotherapy was stopped, and cardioversion
was needed to resuscitate her. She could not undergo
further interventional treatment because we assumed that
her adverse event came from a reaction to ethanol at that
time. Another, 38-year-old female patient showed ST
segment depression on electrocardiogram (ECG) during
ethanol embolotherapy (a total of 28 mL). Her ECG
abnormality normalized with no speciﬁc treatment. Serum
cardiac enzyme levels were also within normal limits. This
patient, however, refused further treatment and was lost
to follow-up. The exact cause of abnormalities in these
two female patients was not fully understood. Distal embo-
lization of the thrombus to the toe artery (1/29 patients)
improved with administration of urokinase and nitroglyc-
erin. One patient had permanent sensory loss.
During a total of 61 embolization sessions, 18 minor
complications were reported (17/61; 28%), and the
average incidence was 0.6 per session. Five major complica-
tions took place (6/61; 10%), with an average incidence
per session of 0.17. There were no mortalities.Transient pulmonary hypertension occurred in nine
patients who required an intensive care unit stay overnight.
They had recovered with no complications.DISCUSSION
Our study is the ﬁrst and the largest one to analyze
AVMs involving only the foot, although there have been
studies on AVMs of different parts of the body (including
some cases of foot AVM) or only the hand.4,9,11,14,15
From our thorough analysis of clinical manifestations,
angiographic ﬁndings and outcomes of ethanol embolo-
therapy, we found several characteristics unique to foot
AVMs.
Ulceration was more commonly observed in the AVM
of the foot in this series. The possible mechanism is chronic
venous hypertension because the foot is located in the
dependent portion of the body. Ulcer was the second
most common symptom in this study (51.7%; 15/29). In
one previous study, the incidence of ulcer was only 10%
(4/40), which included the hand (n ¼ 2), thigh (n ¼2),
and foot (n ¼ 1).10 In addition, whereas older patients
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symptom in younger patients. One possible explanation
for this distinctive feature is that chronic venous hyperten-
sion might cause an ulcer, which began as a pulsating mass.
Only one foot AVM involved a bone, the calcaneus. Most
lower extremity bone AVMs involve the tibia, ﬁbula, or
femur.18 There was no patient with heart failure. Although
the incidence of heart failure in AVM patients has not been
reported, its incidence in foot AVM patients appears to be
lower than other AVMs. This might be due to the smaller
extent of foot AVM, the smaller volume of shunts, and the
longer distance from the heart compared with AVMs in the
upper extremities or trunk. In this retrospective study, no
foot AVM involved toes.
Direct puncture was the most common approach
during ethanol embolotherapy, similar to a report on
hand AVM.14 This might have been due to the tortuous
and smaller arteries of the foot, which make the transarte-
rial approach difﬁcult.
When we analyzed the treatment results, the cure and
improvement rates were better than we expected because
foot AVMs have tortuous, ﬁne arteries that are difﬁcult
to approach with a transarterial catheter and small nidus
to puncture directly. The cure and improvement rates of
24% and 59%, respectively, were comparable to previous
reports of 40% and 28% in body and extremity AVMs,10
3% and 73% in hand AVMs,14 23% and 38% in peripheral
AVMs with glue,11 and 25% and 63% in body and
extremity AVMs.6 Therefore, ethanol embolotherapy
could be an effective treatment modality for foot AVMs.
Treatment failed in two patients. The causes of treatment
failure were intractable pain requiring limb amputation
and superﬁcial location of the lesion that was impossible
to approach via either the transarterial route or direct punc-
ture. In the latter case, surgery was not an option because,
from a surgeon’s point of view, bleeding control was not
possible due to such a rich vasculature in and around the
AVM taking into account angiographic ﬁnding.
The per-patient incidences of minor and major compli-
cations were 52% and 24%, respectively. There was no
procedure-related mortality. These ﬁgures were similar to
the previous reports of approximately 50% for minor and
12% for major complications.6,10 The overall complication
rate was 72%, which is slightly higher than the 10% to
62.5% in previous reports.6,9-11,14,17 However, most minor
complications resolved spontaneously or with only conser-
vative treatment. Furthermore, the incidences of minor and
major complications per embolotherapy session were 0.6
and 0.17, respectively.
Pulmonary artery hypertension is a well-known compli-
cation of ethanol embolotherapy. In this series, nine
patients had transient pulmonary hypertension during the
procedure. All patients were observed overnight in the
intensive care unit and recovered with no complications.
Swan Ganz catheter placement is fundamental to monitor
pulmonary artery pressure. However, patients weighing
less than 30 kg are not feasible for catheter placement. In
our study, the Swan Ganz catheter was not placed innine patients (two for having low body weight and seven
for being expected to require a safe dose). Therefore,
ethanol embolotherapy for foot AVMs does not seem to
be a more dangerous treatment than other modalities
such as embolotherapy using other embolizing agents
than ethanol.
From the analysis of the relationship between the lesion
extent or angiographic type and treatment results, we
reached the promising conclusion that the smaller the
extent of the lesion (<25%), the better the outcome was.
This result, to some extent, is in line with that of hand
AVMs published by Park et al.14 There was, however, no
statistically signiﬁcant correlation between the angio-
graphic type and treatment result.
Our study has several limitations. First, the number of
patients was small. AVM is a rare disease, and foot AVM is
much rarer than AVM of other body parts. This is an
inherent limitation of reports dealing with rare disease enti-
ties. If the number of cases rises, additional studies will be
necessary. The statistical calculations for the relationship
between the lesion extent or angiographic type and treat-
ment result had low power because of the small sample
size. Therefore, we could only detect a relationship
between the lesion extent and treatment result. Finally,
the treatment results were not ﬁnal because some patients
are still under treatment. Therefore, our ﬁnal results will
be published in the future.
In conclusion, ethanol embolotherapy for foot AVMs
can be as effective and safe as in other parts of the body.
Our angiographic ﬁndings suggest that foot AVMs that
involve <25% of the area of the foot can be predicted to
show better treatment outcome.AUTHOR CONTRIBUTIONS
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